Related Experiment Video

Updated: Jul 13, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Recent advances of MEK inhibitors and their clinical progress

John Yuan Wang1, Keith M Wilcoxen, Kenichi Nomoto

  • 1Eisai Research Institute of Boston Inc., 4 Corporate Drive, Andover, MA 01810, USA. yuan_wang@eisai.com

Current Topics in Medicinal Chemistry
|August 19, 2007
PubMed

Insights

This review covers MEK inhibitors targeting the RAS/RAF/MEK/ERK pathway, crucial in oncology. It highlights clinical progress and new drug developments, including ATP-competitive and non-competitive inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The RAS/RAF/MEK/ERK signaling pathway is a key target in cancer research.
  • B-RAF mutations are linked to various cancers, increasing interest in pathway inhibitors.

Purpose of the Study:

  • To review the current understanding and therapeutic applications of MEK inhibitors.
  • To highlight clinical progress of specific MEK inhibitors and discuss new developments.

Main Methods:

  • Literature review of scientific understanding and therapeutic use of MEK inhibitors.
  • Summary of clinical progress for PD0325901 and AZD6244.
  • Discussion of newly disclosed MEK inhibitors based on their classification.

Main Results:

  • MEK inhibitors targeting the RAS/RAF/MEK/ERK pathway are of significant clinical interest.
  • Clinical progress has been made with inhibitors like PD0325901 and AZD6244.
  • New MEK inhibitors are emerging, categorized as ATP non-competitive and ATP competitive.

Conclusions:

  • MEK inhibitors represent a promising therapeutic strategy in oncology.
  • Continued research and development of MEK inhibitors are advancing cancer treatment options.
  • Understanding inhibitor classes is crucial for future drug design and application.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...